Education
About Us
Working with TipRanks
Follow Us
NeurAxis, Inc. (NRXS)
:NRXS
Top Page
NeurAxis, Inc.
(NYSE MKT:NRXS)
47Neutral
NeurAxis, Inc. (NRXS) vs. S&P 500 (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)34.98K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth27.52%
EPS Growth62.82%
CountryUS
Employees21
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding7,215,864
10 Day Avg. Volume26,381
30 Day Avg. Volume34,982
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)7.19
Price to Sales (P/S)0.00
P/FCF Ratio-2.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NeurAxis, Inc. Business Overview & Revenue Model
Company DescriptionNeurAxis, Inc. (NRXS) is a healthcare technology company focused on developing innovative neuromodulation therapies to address unmet medical needs. The company operates primarily in the medical device sector, providing pioneering solutions for the treatment of chronic and acute neurological conditions. Its core products are designed to improve patient outcomes and quality of life by leveraging advanced neuromodulation techniques.
How the Company Makes MoneyNeurAxis, Inc. generates revenue through the sale and licensing of its proprietary neuromodulation devices. Key revenue streams include direct sales to healthcare providers and hospitals, as well as partnerships with medical institutions for the deployment and integration of its technologies. The company may also engage in collaborative agreements with research organizations and pharmaceutical companies to expand the application of its products. Revenue is further bolstered by service agreements for device maintenance and support. NeurAxis's earnings are influenced by the adoption rate of its technologies, regulatory approvals, and its ability to secure strategic partnerships that enhance market penetration.
NeurAxis, Inc. Financial Statement Overview
Summary
NeurAxis shows revenue growth, a positive indicator for a biotech firm, but faces significant challenges with high operating losses and negative equity. Cash flow is under pressure with negative free cash flows, indicating financial instability and risk.Income Statement
NeurAxis has experienced revenue growth from 2023 to 2024, but its profitability remains a concern. The gross profit margin has stayed relatively stable, but net income is deeply negative, indicating significant losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. While the revenue growth is a positive sign, the company struggles with high operating losses.45
Neutral
Balance Sheet
The balance sheet shows critical weaknesses, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged. The equity ratio is also concerning, suggesting financial instability. Overall, the balance sheet reflects significant financial risk.30
Negative
Cash Flow
Cash flow analysis reveals that NeurAxis is burning cash, with negative operating and free cash flows. The company has improved its financing cash flow, which may help sustain operations temporarily. However, the free cash flow to net income ratio is unfavorable, indicating poor cash management relative to earnings. While there's some improvement in cash inflows, the cash flow situation remains a challenge.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.69M | 2.46M | 2.68M | 2.72M | 1.93M | Gross Profit |
| 2.32M | 2.16M | 2.39M | 2.25M | 1.45M | EBIT |
| -7.16M | -6.66M | -3.37M | -2.97M | -4.12M | EBITDA |
| -7.90M | -9.23M | -4.33M | -2.95M | -3.61M | Net Income Common Stockholders |
| -8.24M | -14.63M | -4.78M | -3.07M | -4.05M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.70M | 78.56K | 253.70K | 320.86K | 1.90M | Total Assets |
| 4.76M | 509.50K | 1.48M | 760.48K | 2.79M | Total Debt |
| 216.91K | 224.26K | 598.82K | 439.27K | 311.49K | Net Debt |
| 216.91K | 145.70K | 345.12K | 118.42K | -1.58M | Total Liabilities |
| 2.69M | 1.91M | 7.05M | 1.59M | 1.15M | Stockholders Equity |
| 2.07M | -1.40M | -5.57M | -825.66K | 1.64M |
| Cash Flow | Free Cash Flow | |||
| -6.13M | -6.77M | -2.36M | -2.24M | -4.17M | Operating Cash Flow |
| -6.10M | -6.69M | -2.30M | -2.23M | -4.14M | Investing Cash Flow |
| -27.78K | -71.78K | -61.20K | -1.39K | -27.72K | Financing Cash Flow |
| 9.74M | 6.59M | 2.29M | 661.10K | 6.05M |
NeurAxis, Inc. Technical Analysis
Positive
2.25
Price Trends
2.10
Positive
2.29
Negative
2.63
Negative
Market Momentum
0.05
Negative
54.26
Neutral
75.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXS, the sentiment is Positive. The current price of 2.25 is above the 20-day moving average (MA) of 2.16, above the 50-day MA of 2.10, and below the 200-day MA of 2.63, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 54.26 is Neutral, neither overbought nor oversold. The STOCH value of 75.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRXS.
NeurAxis, Inc. Risk Analysis
NeurAxis, Inc. disclosed 54 risk factors in its most recent earnings report. NeurAxis, Inc. reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeurAxis, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.15B | 3.02 | -44.64% | 2.82% | 16.45% | -0.47% | |
47 Neutral | ― | -2480.49% | ― | 27.52% | 62.82% | ||
45 Neutral | $3.21M | ― | -468.00% | ― | ― | 98.55% | |
30 Underperform | $1.77M | ― | -300.16% | ― | ― | 79.57% | |
29 Underperform | $2.79M | ― | -192.72% | ― | ― | 56.26% | |
27 Underperform | $1.78M | ― | -512.79% | ― | ― | -40.51% | |
25 Underperform | $4.53M | ― | -138.80% | ― | ― | 42.26% |
* Healthcare Sector Average
Performance Comparison
NRXS
NeurAxis, Inc.
2.25
-0.72
-24.24%
SLRX
Salarius Pharmaceuticals
0.83
-3.17
-79.25%
QNRX
Quoin Pharmaceuticals
7.70
-19.08
-71.25%
PCSA
Processa Pharmaceuticals
0.23
-1.71
-88.14%
GRI
GRI Bio
1.50
-93.53
-98.42%
PTIX
Protagenic Therapeutics
3.03
-17.13
-84.97%
NeurAxis, Inc. Earnings Call Summary
Earnings Call Date:May 12, 2025
(Q1-2025)
| % Change Since: 12.50%|
Next Earnings Date:Sep 18, 2025
Earnings Call Sentiment Neutral
NeurAxis demonstrated strong revenue growth and strategic progress with insurance coverage and regulatory milestones. However, challenges remain with insurance coverage and financial impacts due to legal settlements. The overall sentiment is cautiously optimistic, with significant achievements balancing the existing challenges.Q1-2025 Updates
Positive Updates
Consistent Revenue Growth
NeurAxis achieved a 39% increase in revenue in Q1 2025 compared to Q1 2024, marking the third consecutive quarter of double-digit growth.
Expansion of Insurance Coverage
The company increased its covered lives from 4 million to 51 million over the past year.
Category I CPT Code Achievement
NeurAxis received a Category I CPT code, effective January 1, 2026, expected to facilitate easier billing and increase revenue.
FDA Approvals and Product Expansion
Expanded IB-Stim label to treat patients aged 8 to 21, and received FDA clearance for RED, a rectal expulsion device.
High Gross Margin
Despite challenges, the company maintained a gross margin of 84.4% in Q1 2025.
Negative Updates
Legal Settlement Expenses
The company incurred a one-time legal settlement charge, impacting operating expenses.
Continued Challenges with Insurance Coverage
Despite progress, lack of comprehensive insurance coverage still poses a barrier to revenue growth, with financial assistance sales being 65% below list price.
Operating Loss Increase
Operating loss increased by 25% compared to Q1 2024, primarily due to the legal settlement charge.
Company Guidance
During NeurAxis' First Quarter 2025 Results and Update Call, the company provided guidance indicating strong financial performance and promising growth prospects. The CEO, Brian Carrico, highlighted a significant revenue trajectory with consistent double-digit growth over the past three quarters, including a 39% increase in Q1 2025. The company is focused on expanding insurance policy coverage, which has grown from 4 million to 51 million covered lives, and anticipates further revenue acceleration upon the implementation of the Category I CPT code effective January 1, 2026. NeurAxis also achieved an 84.4% gross margin this quarter, despite higher manufacturing costs, and aims for cash flow breakeven by leveraging strong data and academic society endorsements. Additionally, the FDA clearance for their RED device and expansion of the IB-Stim label are expected to significantly broaden market opportunities. The CFO, Tim Henrichs, noted an operating loss improvement when excluding a one-time legal settlement, and reaffirmed the company's strategic focus on cost management and sales growth to achieve profitability.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.